Intec Pharma Ltd. (NTEC)’s Trend Down, Especially After Today’s 52-Week Low Hit

June 17, 2018 - By Robert Crowder

Intec Pharma Ltd. (NASDAQ:NTEC) Logo

The stock of Intec Pharma Ltd. (NASDAQ:NTEC) hit a new 52-week low and has $3.86 target or 8.00 % below today’s $4.20 share price. The 6 months bearish chart indicates high risk for the $139.72M company. The 1-year low was reported on Jun, 17 by Barchart.com. If the $3.86 price target is reached, the company will be worth $11.18 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 1.18% or $0.05 during the last trading session, reaching $4.2. About 206,233 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has declined 17.59% since June 17, 2017 and is downtrending. It has underperformed by 30.16% the S&P500.

Analysts await Intec Pharma Ltd. (NASDAQ:NTEC) to report earnings on August, 8. They expect $-0.30 earnings per share, up 36.17 % or $0.17 from last year’s $-0.47 per share. After $-0.41 actual earnings per share reported by Intec Pharma Ltd. for the previous quarter, Wall Street now forecasts -26.83 % EPS growth.

Another recent and important Intec Pharma Ltd. (NASDAQ:NTEC) news was published by Benzinga.com which published an article titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $139.72 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients.

Intec Pharma Ltd. (NASDAQ:NTEC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: